$RTGN
RetinalGenix Technologies Inc.

2023 Q1 Form 10-K Financial Statement

#000149315223010215 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $281.8K $356.2K $1.067M
YoY Change -28.71%
% of Gross Profit
Research & Development $227.9K $317.8K $809.3K
YoY Change 44.73% 8.22%
% of Gross Profit
Depreciation & Amortization $25.00 $20.00 $51.00
YoY Change
% of Gross Profit
Operating Expenses $509.7K $674.0K $3.909M
YoY Change 36.37% 79.58%
Operating Profit
YoY Change
Interest Expense $960.00 -$960.00 $5.140K
YoY Change -34.25% 96.26%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$510.6K -$675.0K -$3.914M
YoY Change 79.6%
Income Tax
% Of Pretax Income
Net Earnings -$510.6K -$675.0K -$3.914M
YoY Change 36.1% 79.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.25
Diluted Earnings Per Share -$0.03 -$0.04 -$0.23
COMMON SHARES
Basic Shares Outstanding 17.27M shares 17.27M shares 15.58M shares
Diluted Shares Outstanding 17.27M shares 15.58M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.470K $40.00 $40.00
YoY Change -99.19%
Cash & Equivalents $7.470K $38.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.470K $38.00 $40.00
YoY Change -99.23% -99.19%
LONG-TERM ASSETS
Property, Plant & Equipment $231.00 $256.00 $260.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $231.00 $256.00 $250.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $7.470K $38.00 $40.00
Total Long-Term Assets $231.00 $256.00 $250.00
Total Assets $7.701K $294.00 $290.00
YoY Change -94.06% -94.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $634.2K $475.5K $475.5K
YoY Change 89.22% 89.22%
Accrued Expenses $8.720K $7.760K $7.760K
YoY Change 196.18%
Deferred Revenue
YoY Change
Short-Term Debt $49.00K $49.00K $49.00K
YoY Change -32.88%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.509M $1.069M $1.069M
YoY Change 127.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.509M $1.069M $1.069M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.509M $1.069M $1.069M
YoY Change 127.63% 127.71%
SHAREHOLDERS EQUITY
Retained Earnings -$9.529M -$9.018M
YoY Change 76.67%
Common Stock $1.783K $1.783K
YoY Change 25.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.501M -$1.069M -$1.069M
YoY Change
Total Liabilities & Shareholders Equity $7.701K $294.00 $290.00
YoY Change -94.06% -94.14%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$510.6K -$675.0K -$3.914M
YoY Change 36.1% 79.6%
Depreciation, Depletion And Amortization $25.00 $20.00 $51.00
YoY Change
Cash From Operating Activities -$77.58K -$33.25K -$199.3K
YoY Change -19.85% -82.92%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $310.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$310.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $60.50K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $85.01K 29.66K $194.7K
YoY Change -9.95% -83.36%
NET CHANGE
Cash From Operating Activities -$77.58K -33.25K -$199.3K
Cash From Investing Activities 0.000 -310.0
Cash From Financing Activities $85.01K 29.66K $194.7K
Net Change In Cash $7.432K -3.590K -$4.909K
YoY Change -410.7% -279.95%
FREE CASH FLOW
Cash From Operating Activities -$77.58K -$33.25K -$199.3K
Capital Expenditures $0.00 $310.00
Free Cash Flow -$33.25K -$199.6K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001836295
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2021Q4 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
usd
CY2021 RGTS Stock Issued During Period Value For Exchange Of Shares
StockIssuedDuringPeriodValueForExchangeOfShares
usd
CY2021 RGTS Stock Issued During Period Value For Recission Of Preferred Stock
StockIssuedDuringPeriodValueForRecissionOfPreferredStock
usd
CY2021 RGTS Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
usd
CY2021 us-gaap Depreciation
Depreciation
usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
usd
CY2021 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022 RGTS Exchange Of Common Stock For Prefunded Warrants
ExchangeOfCommonStockForPrefundedWarrants
usd
CY2021 RGTS Repayment Of Shareholders Note Payable Through Exercise Of Warrants
RepaymentOfShareholdersNotePayableThroughExerciseOfWarrants
usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2021 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
333-258528
CY2022 dei Entity Registrant Name
EntityRegistrantName
RETINALGENIX TECHNOLOGIES INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3936890
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1450 North McDowell Boulevard
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Petaluma
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14221814 shares
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94954
CY2022 dei City Area Code
CityAreaCode
(415)
CY2022 dei Local Phone Number
LocalPhoneNumber
578-9583
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
13659720 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17272116 shares
CY2022 dei Auditor Name
AuditorName
Liebman Goldberg & Hymowitz, LLP
CY2022 dei Auditor Location
AuditorLocation
Garden City, New York
CY2022 dei Auditor Firm
AuditorFirmId
473
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4947 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
4947 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
52 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256 usd
CY2022Q4 us-gaap Assets
Assets
294 usd
CY2021Q4 us-gaap Assets
Assets
4947 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
475480 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
251282 usd
CY2022Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
427933 usd
CY2021Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
142721 usd
CY2022Q4 us-gaap Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
109185 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
49000 usd
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
73000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2619 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069357 usd
CY2021Q4 us-gaap Liabilities
Liabilities
469622 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17272116 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17272116 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14221814 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1783 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1423 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7947460 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4638218 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9018306 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5104316 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-464675 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4947 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
807406 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1120949 usd
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
809255 usd
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
747808 usd
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2032889 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
259300 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
307918 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
3908850 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
2176675 usd
CY2022 us-gaap Interest Expense
InterestExpense
5140 usd
CY2021 us-gaap Interest Expense
InterestExpense
2619 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2179294 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15584346 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41246915 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-80356 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1083199 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
307918 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13500 usd
CY2021 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
390358 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2179294 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-464675 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-464675 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
259300 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60500 usd
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
939802 usd
CY2022 RGTS Stock Issued During Period Value Warrant And Stock Options Exercised
StockIssuedDuringPeriodValueWarrantAndStockOptionsExercised
50000 usd
CY2022 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
2000000 shares
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2000000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3913990 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2179294 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
259300 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
307918 usd
CY2022 RGTS Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
2000000 usd
CY2022 us-gaap Depreciation
Depreciation
51 usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
1225014 usd
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
548148 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
225198 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
109851 usd
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-43787 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
5140 usd
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2619 usd
CY2022 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3714703 usd
CY2021 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1012323 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-199287 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1166971 usd
CY2022 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
307 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60500 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1083199 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13500 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
73000 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
109185 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194685 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1169699 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4909 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2728 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4947 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2219 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4947 usd
CY2022 us-gaap Stock Issued1
StockIssued1
939802 usd
CY2021 us-gaap Stock Issued1
StockIssued1
390358 usd
CY2021 RGTS Exchange Of Common Stock For Prefunded Warrants
ExchangeOfCommonStockForPrefundedWarrants
-2801 usd
CY2022 RGTS Repayment Of Shareholders Note Payable Through Exercise Of Warrants
RepaymentOfShareholdersNotePayableThroughExerciseOfWarrants
25000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9018000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
470000 usd
CY2022Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
428000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zVGfaQuc2lu9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_869_zTxPEoylO496">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company’s financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Price
SharePrice
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
142721 usd
CY2020Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
-15069 usd
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
79290 usd
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
68073 usd
CY2022 us-gaap Related Party Costs
RelatedPartyCosts
453047 usd
CY2021 us-gaap Related Party Costs
RelatedPartyCosts
803997 usd
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-692677 usd
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
323922 usd
CY2022 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
939802 shares
CY2021 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
390358 shares
CY2022Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
427933 usd
CY2021Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
142721 usd
CY2022Q4 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
109185 usd
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The right to elect two directors shall terminate on the date upon which there are less than 25,000 shares of Series F preferred stock issued and outstanding.
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
655000 usd
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5115000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1800000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
82500 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1882500 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
502500 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2360000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2360000 shares
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1204444 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
525000 shares
CY2021Q4 RGTS Fair Value Of Share Price
FairValueOfSharePrice
0.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.731 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q4 us-gaap Share Price
SharePrice
1.00
CY2022Q4 RGTS Fair Value Of Share Price
FairValueOfSharePrice
0.56
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0219 pure
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
62500 shares
CY2020Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
150000 shares
CY2021 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted
1.10
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
13500 shares
CY2021 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised
1.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
199000 shares
CY2021Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.07
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
12500 shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
25000 shares
CY2022 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
161500 shares
CY2022Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.09
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
161500 shares
CY2022Q4 RGTS Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
161500 shares
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
73000 usd
CY2021Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2021 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-12-31
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
CY2022 RGTS Warrant Exercises Outstanding
WarrantExercisesOutstanding
48000 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
5140 usd
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
2619 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2619 usd
CY2022 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
the Company had net operating loss carryforwards (“NOL”) of approximately $4,499,000 for federal income tax purposes of which $3,724,000 has no expiration date, $775,000 which begins to expire in 2034, and approximately $4,499,000 for state income tax purposes which begins to expire in 2030
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4499000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1714000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1350000 usd
CY2022Q4 RGTS Deferred Tax Assets Applicable To Accruals
DeferredTaxAssetsApplicableToAccruals
236000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
128000 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1193000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
992000 usd
CY2021Q4 RGTS Deferred Tax Assets Applicable To Accruals
DeferredTaxAssetsApplicableToAccruals
158000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
43000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
521000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
389000 usd

Files In Submission

Name View Source Status
rgts-20221231_lab.xml Edgar Link unprocessable
0001493152-23-010215-index-headers.html Edgar Link pending
0001493152-23-010215-index.html Edgar Link pending
0001493152-23-010215.txt Edgar Link pending
0001493152-23-010215-xbrl.zip Edgar Link pending
ex21-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex4-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgts-20221231.xsd Edgar Link pending
Show.js Edgar Link pending
rgts-20221231_cal.xml Edgar Link unprocessable
rgts-20221231_def.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
rgts-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable